Evidence map›Paper›PMID 40070132›Full record

ArticleJournal of medicinal chemistry2025

UNC9426, a Potent and Orally Bioavailable TYRO3-Specific Inhibitor.

Deyu Kong, Xiangbo Yang, Samantha Judd, Dan Yan, Stephanie Springborn, Michael A Stashko, Adam Kidwell, Justus M Huelse, Dmitri Kireev, Douglas K Graham and 3 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Deyu KongCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Xiangbo YangCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Samantha JuddVersiti Blood Research Institute, Wauwatosa, Wisconsin 53226, United States.
Dan YanAflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, United States.
Stephanie SpringbornVersiti Blood Research Institute, Wauwatosa, Wisconsin 53226, United States.
Michael A StashkoCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Adam KidwellVersiti Blood Research Institute, Wauwatosa, Wisconsin 53226, United States.
Justus M HuelseAflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, United States.
Dmitri KireevCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8479-8555
Douglas K GrahamAflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, United States.
Deborah DeRyckereAflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, United States.
Brian BranchfordVersiti Blood Research Institute, Wauwatosa, Wisconsin 53226, United States.
Xiaodong WangCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-3293-7538

Funding

Research Training in Pediatric Non-Malignant HematologyT32HL139443 · NHLBI · EMORY UNIVERSITY · PI Clinton H Joiner, Shannon L. Meeks · 2018 to 2026
$2.6M
Novel TYRO3 inhibitors for treatment of cancerR01CA259077 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GRAHAM, DOUGLAS K, WANG, XIAODONG · 2021 to 2025
$1.6M
The role in inflammation in platelet activation and thrombosisK08HL146941 · NHLBI · VERSITI WISCONSIN, INC. · PI BRANCHFORD, BRIAN R · 2020 to 2024
$810k
NCI NIH HHS R01 CA259077NHLBI NIH HHS K08 HL146941NHLBI NIH HHS T32 HL139443
6 · The paper itself

Abstract

TYRO3 plays a critical role in platelet aggregation as a platelet response amplifier. Selective inhibition of TYRO3 may provide therapeutic benefits for treating thrombosis and related diseases without increasing bleeding risk. We employed a structure-based approach and discovered a novel and potent TYRO3 inhibitor UNC9426 (

Indexed as

Platelet AggregationAdministration, OralAnimalsBiological AvailabilityHumansMaleMicePlatelet Aggregation InhibitorsReceptor Protein-Tyrosine KinasesStructure-Activity RelationshipPlatelet Aggregation InhibitorsReceptor Protein-Tyrosine KinasesTYRO3 protein, human

Identifiers

PMID40070132
PMCPMC12063470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.